Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, con­firm­ing Wednes­day that it has dropped the as­set.

The com­pa­ny had …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER